Ahmed Selim

• Led the sales and marketing efforts for Skyrizi, a treatment for psoriasis, across multiple Gulf countries.
• Maintained market leadership for 22 months post-launch, achieving a 37% market share in the region.
• Developed and implemented tailored marketing and sales strategies to drive Skyrizi unit ambition, including initiatives such as "Sky Stories," "Up To 100," and "Close the Psoriatic Loop."
• Successfully penetrated 95% of Gulf accounts, exceeding planned sales and market share targets for three consecutive years.
• Managed profit and loss (P&L) in alignment with the finance team to ensure maximum productivity and profitability.
• Cultivated strong partnerships between AbbVie and governmental sectors through the implementation of patient-centric projects, notably the "Donn't Rest Until It's Clear Campaign."
• Effectively managed budgets and allocated resources to optimize performance.
• Cultivated a highly productive culture within the team, resulting in a remarkable 97% engagement rate in the employee survey.
• Established productive relationships with key stakeholders, ensuring alignment of business objectives

This role underscores my proficiency in driving successful sales and marketing strategies, effective P&L management, and cultivating strategic partnerships to drive business growth within the pharmaceutical sector. Additionally, my focus on fostering a productive team culture has led to exceptional levels of employee engagement and performance.

• Led the sales and marketing efforts for Rinvoq in Atopic Dermatitis across multiple Gulf countries.
• Initiated pre-launch activities 18 months prior to launch, setting the overall brand strategy, regulatory timelines, access timelines, and recruiting the team.
• Conducted comprehensive market analysis to inform decision-making and strategic planning, including organizing 2 Medical Ad-Boards, 1 Marketing Ad-Board, 1 PSP Ad-Board, and executing 2 waves of market research.
• Cultivated strong partnerships between AbbVie and governmental sectors through the implementation of patient-centric projects, notably the Atopic Dermatitis Awareness Campaigns.
• Fostered strong team dynamics through regular communication, resulting in improved performance and achieving 80% brand access in all Gulf countries within only 6 months after the launch, with a 10% market share in the UAE.
• Successfully managed budgets and allocated resources to maximize productivity and profitability.
• Took full responsibility for managing profit and loss (P&L) in alignment with the finance team, ensuring financial objectives were met.
• Facilitated cross-functional collaboration, fostering an environment of teamwork and innovation.

This experience highlights my ability to lead successful pre-launch strategies, conduct thorough market analysis, develop strong partnerships, and foster a culture of teamwork and innovation. Additionally, the effective budget management and alignment with financial goals.

• Led pre-launch activities for Skyrizi in Psoriasis and Rinvoq in Atopic Dermatitis indications, meticulously setting the groundwork for successful brand launches.
• Orchestrated the digital and physical launch of both brands across the five Gulf countries, ensuring comprehensive market coverage.
• Spearheaded the April 2020 digital launch of Skyrizi amidst the COVID-19 pandemic, introducing the innovative RiziTalks initiative. Recognized in the Mind Share, it was celebrated globally as one of the best initiatives during COVID.
• Demonstrated a deep understanding of the patient journey to identify and establish pivotal moments of significance.
• Managed annual brand expenditure and executed partnership programs with relevant societies.
• Provided ongoing brand training for teams and monitored competitors' strategies.

This experience showcases my ability to lead successful brand launches, understand market dynamics, manage budgets, and drive strategic initiatives in the pharmaceutical sector.

Immunology & Bone health

• Driving Prolia® "market leader in Osteoporosis with 38% MS" performance in Saudi market.
• Introduction& launch of Amgevita® in Saudi market (pre-launch phase and Post Launch)
• Introduction& launch of Evenity® in Saudi market (pre-launch phase)
• Managed large-scale projects and introduced new systems, tools, and processes to achieve challenging objectives.
• Boosted team member productivity by enhancing performance monitoring and instituting motivational approaches.

Nephrology - Anesthesia

• Managing Sevoflorane anesthesia brand keeping market leadership although 3 generics
• Holding market leadership in Sevorane with 81% MS among inhalation anesthesia market
• Re-brand Sevoflorane with trust campaign
• Launch of Zemplar capsule in 2017 with new concept and story board from scratch
• Got market leadership with Zemplar in 2017 just after 3 years of launch with MS 49%

Humira

• Launch of new indication of Humira in Ulcerative colitis
• Co-launch AbbVie HCV portfolio with Gastroenterologist in KSA

Diabetes and Metabolism

• Diabetes franchise (Onglyza - Byetta)

Diabetes and CVS

CVS, & Diabetes line (Diamicron - Coveram - Procoralan)

Chest and Pulomnology

(Sympicort -Pulmicort) in Cairo and Delta governorates